Comparable order intake was in line with Q3 2018. The Diagnosis & Treatment businesses recorded 9% comparable sales growth, with double-digit growth in Ultrasound and high-single-digit growth in Diagnostic Imaging and Image-Guided Therapy. For 2020, we expect 4-6% comparable sales growth and an Adjusted EBITA margin improvement of around 100 basis points.” We expect the Adjusted EBITA margin to improve around 10 to 20 basis points given the overall significant headwinds and the performance trajectory of the Connected Care businesses, which we are addressing. Adjusted EBITA for the Group was also impacted by lower license income in the segment Other.įor the full-year 2019, we continue to expect growth to be within the 4-6% range. However, as we announced in our update on October 10, 2019, the Adjusted EBITA margin in the Connected Care businesses declined to 11.3%, due to increasing headwinds from tariffs and a delay in the impact of the mitigating actions, factory under-coverage and an adverse product mix impact. The Adjusted EBITA margin in the Diagnosis & Treatment and Personal Health businesses showed continued improvement. Over the last 12 months, comparable order intake grew 5%. This was reflected in the mid-single-digit comparable sales growth in mature geographies and high-single-digit growth in growth geographies, with double-digit growth in China.Ĭomparable order intake was flat, on the back of strong 11% growth in the third quarter of 2018, reflecting the unevenness of order intake dynamics and softness in North America. We recorded strong 6% comparable sales growth, driven by the innovative products and solutions across our businesses. “In the third quarter, we delivered mixed results for the Group. Operating cash flow increased to EUR 356 million, compared to EUR 265 million in Q3 2018 free cash flow increased to EUR 126 million, compared to EUR 52 million in Q3 2018.EPS from continuing operations (diluted) amounted to EUR 0.23 Adjusted EPS from continuing operations (diluted) increased 10% compared to Q3 2018 to EUR 0.46.Income from operations amounted to EUR 320 million, compared to EUR 451 million in Q3 2018.Adjusted EBITA margin was 12.4% of sales, compared to 13.2% of sales in Q3 2018.Income from continuing operations amounted to EUR 211 million, including a charge of EUR 78 million related to a goodwill impairment, compared to EUR 307 million in Q3 2018.Comparable order intake was in line with Q3 2018.Sales in the quarter amounted to EUR 4.7 billion, with 6% comparable sales growth.
0 Comments
Leave a Reply. |